Publications by authors named "Cansu Dogan Dalkıran"
Dermatol Ther
November 2022
Article Synopsis
- There is a significant need for effective treatment options for hidradenitis suppurativa (HS), despite existing approved therapies.
- This study evaluated the effectiveness of certolizumab pegol in 11 severe HS patients who had not responded to adalimumab, observing clinical responses after 12 and 24 weeks of treatment.
- Results showed that 54.5% of patients achieved a clinical response at week 12, and there were significant improvements in quality of life and severity scores, suggesting that certolizumab pegol could be a viable treatment for hard-to-treat HS cases.
